Keith M. Dawson
Schlieren, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.
Journal: EJHaem
Published: June 06, 2024
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
Journal: Cancer immunology research
Published: August 24, 2023
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Journal: JCO precision oncology
Published: November 04, 2022
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants.
Journal: Nature biotechnology
Published: December 14, 2021
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 10, 2020
Beyond Antibodies: The DARPin® Drug Platform.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: June 26, 2020
MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.
Journal: Oncotarget
Published: July 13, 2017
A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants.
Journal: Blood cancer journal
Published: October 03, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026